Spermatocytic tumor is a rare type of testicular germ cell tumor, accounting for approximately 1% of all testicular neoplasms.
Case Presentation
A 51-year-old male presented to the hospital with a painless mass in the left testis. Ultrasonography revealed a heterogeneous intratesticular mass with cystic components. Testicular tumor markers were within normal ranges. The patient underwent a left orchiectomy. Pathologically, the tumor was characterized by the presence of medium to large neoplastic cells and small neoplastic cells without sarcomatoid or anaplastic features. Immunohistochemically, the tumor was positive for SALL4 and negative for CD30, AFP, OCT3/4, PLAP, D2-40, and hCG. Based on these findings, we diagnosed spermatocytic tumor of testis.
Conclusion
We present a case of spermatocytic tumor, which is a distinct entity among testicular germ cell tumors, with a generally favorable prognosis following orchiectomy. However, long-term follow-up is recommended due to the potential for late metastasis.
{"title":"A Case of Spermatocytic Tumor of Testis","authors":"Satsuki Nagamine, Yosuke Nakanishi, Kei Tanaka, Asuka Ashikari, Ryu Kimura, Shotaro Nakanishi, Rin Kawamitsu, Naoki Wada, Akihiro Nishie, Junichi Inokuchi","doi":"10.1002/iju5.70089","DOIUrl":"https://doi.org/10.1002/iju5.70089","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Spermatocytic tumor is a rare type of testicular germ cell tumor, accounting for approximately 1% of all testicular neoplasms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>A 51-year-old male presented to the hospital with a painless mass in the left testis. Ultrasonography revealed a heterogeneous intratesticular mass with cystic components. Testicular tumor markers were within normal ranges. The patient underwent a left orchiectomy. Pathologically, the tumor was characterized by the presence of medium to large neoplastic cells and small neoplastic cells without sarcomatoid or anaplastic features. Immunohistochemically, the tumor was positive for SALL4 and negative for CD30, AFP, OCT3/4, PLAP, D2-40, and hCG. Based on these findings, we diagnosed spermatocytic tumor of testis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We present a case of spermatocytic tumor, which is a distinct entity among testicular germ cell tumors, with a generally favorable prognosis following orchiectomy. However, long-term follow-up is recommended due to the potential for late metastasis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 6","pages":"563-566"},"PeriodicalIF":0.0,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70089","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Inflammatory myofibroblastic tumor (IMT) of the bladder is a rare benign tumor characterized by atypical spindle cell proliferation and inflammatory cell infiltration, typically involving lymphocytes and plasma cells.
Case Presentation
A 38-year-old woman presented with micturition pain and urinary frequency. Cystoscopy revealed an elevated tumor with edematous mucosa on the anterior bladder wall. Transurethral resection confirmed IMT of the bladder but was incomplete, prompting laparoscopic partial cystectomy with cystoscopy guidance. At 2-year follow-up, the patient remained asymptomatic with no recurrence.
Conclusion
Complete resection is the standard treatment for bladder IMT. When the tumor extends beyond the bladder wall, laparoscopic partial cystectomy with cystoscopy guidance offers a safe and effective surgical approach for achieving complete resection with adequate margins.
{"title":"Laparoscopic Partial Cystectomy for Inflammatory Myofibroblastic Tumor of the Urinary Bladder","authors":"Hajime Yamasaki, Shigeaki Nakazawa, Kentaro Takezawa, Taigo Kato, Koji Hatano, Yoichi Kakuta, Atsunari Kawashima, Shinichiro Fukuhara, Norio Nonomura","doi":"10.1002/iju5.70100","DOIUrl":"https://doi.org/10.1002/iju5.70100","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Inflammatory myofibroblastic tumor (IMT) of the bladder is a rare benign tumor characterized by atypical spindle cell proliferation and inflammatory cell infiltration, typically involving lymphocytes and plasma cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>A 38-year-old woman presented with micturition pain and urinary frequency. Cystoscopy revealed an elevated tumor with edematous mucosa on the anterior bladder wall. Transurethral resection confirmed IMT of the bladder but was incomplete, prompting laparoscopic partial cystectomy with cystoscopy guidance. At 2-year follow-up, the patient remained asymptomatic with no recurrence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Complete resection is the standard treatment for bladder IMT. When the tumor extends beyond the bladder wall, laparoscopic partial cystectomy with cystoscopy guidance offers a safe and effective surgical approach for achieving complete resection with adequate margins.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 6","pages":"604-607"},"PeriodicalIF":0.0,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70100","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Partial splenic embolization is a valuable option to manage hypersplenism and reduce portal pressure while preserving splenic function. It may improve surgical safety in patients with portal hypertension.
Case Presentation
A 67-year-old Japanese male with renal cell carcinoma and hepatitis B-related liver cirrhosis presented with thrombocytopenia, collateral vessels, and a splenorenal shunt. Due to concerns regarding surgical risk, partial splenic embolization was performed preoperatively. Following the procedure, the platelet count increased, and collateral circulation decreased. These improvements enabled a safe left radical nephrectomy.
Conclusion
Partial splenic embolization can be an effective preoperative strategy in patients with renal tumors and coexisting portal hypertension. By improving hematologic parameters and reducing vascular risk, it may facilitate curative surgery in high-risk patients and expand treatment options.
{"title":"Partial Splenic Embolization for Portal Hypertension Before Radical Nephrectomy in Renal Cell Carcinoma Patient: A Case Report","authors":"Shunsuke Watanabe, Keita Tamura, Kyohei Watanabe, Yuto Matsushita, Hiromitsu Watanabe, Daisuke Motoyama, Teruo Inamoto","doi":"10.1002/iju5.70108","DOIUrl":"https://doi.org/10.1002/iju5.70108","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Partial splenic embolization is a valuable option to manage hypersplenism and reduce portal pressure while preserving splenic function. It may improve surgical safety in patients with portal hypertension.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>A 67-year-old Japanese male with renal cell carcinoma and hepatitis B-related liver cirrhosis presented with thrombocytopenia, collateral vessels, and a splenorenal shunt. Due to concerns regarding surgical risk, partial splenic embolization was performed preoperatively. Following the procedure, the platelet count increased, and collateral circulation decreased. These improvements enabled a safe left radical nephrectomy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Partial splenic embolization can be an effective preoperative strategy in patients with renal tumors and coexisting portal hypertension. By improving hematologic parameters and reducing vascular risk, it may facilitate curative surgery in high-risk patients and expand treatment options.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 6","pages":"625-629"},"PeriodicalIF":0.0,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70108","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Posterior lumbar interbody fusion (PLIF) is effective for lumbar degenerative disorders, but rare complications such as anterior cage migration may occur. Surgical removal is usually performed via open or transperitoneal laparoscopic approaches.
Case Presentation
An 80-year-old woman underwent PLIF, during which a cage migrated anteriorly and was not retrieved intraoperatively. Postoperative CT revealed the cage positioned between the inferior vena cava (IVC) and right renal arteries. Although asymptomatic, she was referred for surgical removal to prevent potential vascular complications. A laparoscopic retroperitoneal approach was performed, allowing direct access to the cage without vascular injury. The procedure was completed safely with minimal blood loss and no complications.
Conclusion
This is the first reported case of anteriorly migrated cage removal via a retroperitoneal laparoscopic approach. For experienced surgeons, this method offers a minimally invasive and effective alternative to traditional techniques, with potential benefits including reduced surgical morbidity and quicker recovery.
{"title":"Laparoscopic Retroperitoneal Removal of an Anteriorly Migrated Interbody Cage Following Posterior Lumbar Interbody Fusion: A Case Report","authors":"Masaki Yamagata, Kosuke Hamada, Kouki Kanata, Kouhei Iimori, Kiyoaki Funao, Tomoaki Tanaka","doi":"10.1002/iju5.70104","DOIUrl":"https://doi.org/10.1002/iju5.70104","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Posterior lumbar interbody fusion (PLIF) is effective for lumbar degenerative disorders, but rare complications such as anterior cage migration may occur. Surgical removal is usually performed via open or transperitoneal laparoscopic approaches.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>An 80-year-old woman underwent PLIF, during which a cage migrated anteriorly and was not retrieved intraoperatively. Postoperative CT revealed the cage positioned between the inferior vena cava (IVC) and right renal arteries. Although asymptomatic, she was referred for surgical removal to prevent potential vascular complications. A laparoscopic retroperitoneal approach was performed, allowing direct access to the cage without vascular injury. The procedure was completed safely with minimal blood loss and no complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This is the first reported case of anteriorly migrated cage removal via a retroperitoneal laparoscopic approach. For experienced surgeons, this method offers a minimally invasive and effective alternative to traditional techniques, with potential benefits including reduced surgical morbidity and quicker recovery.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 6","pages":"617-620"},"PeriodicalIF":0.0,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70104","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We report a case of vesicovaginal fistula (VVF) following transvaginal mesh (TVM) surgery that was successfully treated conservatively using a urethral catheter with low-pressure intermittent suction.
Case Presentation
A 78-year-old woman underwent TVM surgery for cystocele. During the surgery, bladder perforation occurred, which was repaired transvaginally. After the urethral catheter removal, she was diagnosed with VVF. We reinserted a new urethral catheter and added low-pressure intermittent suction to the catheter, which gradually decreased the amount of incontinence, and the patient was successfully cured.
Conclusion
Urethral catheter with low-pressure intermittent suction may be an option when catheterization alone does not provide adequate drainage of VVF.
{"title":"A Case of Vesicovaginal Fistula After Transvaginal Mesh Surgery Cured by Placement of a Urethral Catheter With Low-Pressure Intermittent Suction","authors":"Miyamoto Madoka, Fujihara Atsuko, Saito Yumiko, Kawahara Marina, Ukimura Osamu","doi":"10.1002/iju5.70105","DOIUrl":"https://doi.org/10.1002/iju5.70105","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>We report a case of vesicovaginal fistula (VVF) following transvaginal mesh (TVM) surgery that was successfully treated conservatively using a urethral catheter with low-pressure intermittent suction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>A 78-year-old woman underwent TVM surgery for cystocele. During the surgery, bladder perforation occurred, which was repaired transvaginally. After the urethral catheter removal, she was diagnosed with VVF. We reinserted a new urethral catheter and added low-pressure intermittent suction to the catheter, which gradually decreased the amount of incontinence, and the patient was successfully cured.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Urethral catheter with low-pressure intermittent suction may be an option when catheterization alone does not provide adequate drainage of VVF.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 6","pages":"621-624"},"PeriodicalIF":0.0,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70105","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Combined rectal impalement (RI) and bladder perforation (BP) is an extremely rare injury pattern, with limited case reports and no established consensus on their diagnosis and management.
Case Presentation
A 50-year-old man sustained a perianal impalement injury caused by a metal rod at a construction site. He presented with perianal pain and gross hematuria (GH). Imaging revealed RI and extraperitoneal BP. A colostomy was performed on the same day as the injury, and transurethral coagulation of the bladder (TUC) was performed on the 6th day, during which a bladder mucosal defect was identified. Postoperatively, the GH reduced, and no persistent voiding or defecation dysfunction was observed.
Conclusion
In patients with RI and GH, concomitant BP should be suspected. Although colostomy is almost always required for rectal injury, extraperitoneal BP can be cured with transurethral intervention and catheterization.
{"title":"A Case of Bladder Perforation With Rectal Impalement Injury","authors":"Tatsuma Juichi, Atsushi Fujikawa","doi":"10.1002/iju5.70101","DOIUrl":"https://doi.org/10.1002/iju5.70101","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Combined rectal impalement (RI) and bladder perforation (BP) is an extremely rare injury pattern, with limited case reports and no established consensus on their diagnosis and management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>A 50-year-old man sustained a perianal impalement injury caused by a metal rod at a construction site. He presented with perianal pain and gross hematuria (GH). Imaging revealed RI and extraperitoneal BP. A colostomy was performed on the same day as the injury, and transurethral coagulation of the bladder (TUC) was performed on the 6th day, during which a bladder mucosal defect was identified. Postoperatively, the GH reduced, and no persistent voiding or defecation dysfunction was observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In patients with RI and GH, concomitant BP should be suspected. Although colostomy is almost always required for rectal injury, extraperitoneal BP can be cured with transurethral intervention and catheterization.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 6","pages":"608-611"},"PeriodicalIF":0.0,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70101","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Large cell neuroendocrine carcinoma (LCNEC) of the bladder is rare and aggressive. Reports of metastasectomy for single distant metastases are even rarer.
Case Presentation
A 49-year-old man was admitted to our hospital with gross hematuria. Cystoscopy, magnetic resonance imaging, and computed tomography revealed invasive bladder cancer without metastasis. He underwent transurethral resection of the bladder tumor, and histopathological examination confirmed LCNEC. The patient received neoadjuvant chemotherapy followed by partial cystectomy. Nineteen months postoperatively, a solitary metastasis was detected in the right axillary lymph node, and at 44 months, another solitary metastasis appeared in the subcutaneous tissue outside the right scapula. Both metastases were surgically resected, and no additional treatment was administered. At the time of this writing, there had been no recurrence or metastasis for 42 months following the second metastasectomy.
Conclusion
Metastasectomy may be an effective treatment option for solitary metastasis of LCNEC of the bladder.
{"title":"A Case of Large Cell Neuroendocrine Carcinoma of the Bladder With Long-Term Control by Metastasectomy","authors":"Naoto Takaoka, Kosuke Kobayashi, Takehiro Yamane, Kazuma Hiramatsu, Kazunari Tsuchihashi, Hiroaki Kawanishi, Hiroyasu Yamashiro, Tomitaka Nakayama, Kazuhiro Okumura","doi":"10.1002/iju5.70102","DOIUrl":"https://doi.org/10.1002/iju5.70102","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Large cell neuroendocrine carcinoma (LCNEC) of the bladder is rare and aggressive. Reports of metastasectomy for single distant metastases are even rarer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>A 49-year-old man was admitted to our hospital with gross hematuria. Cystoscopy, magnetic resonance imaging, and computed tomography revealed invasive bladder cancer without metastasis. He underwent transurethral resection of the bladder tumor, and histopathological examination confirmed LCNEC. The patient received neoadjuvant chemotherapy followed by partial cystectomy. Nineteen months postoperatively, a solitary metastasis was detected in the right axillary lymph node, and at 44 months, another solitary metastasis appeared in the subcutaneous tissue outside the right scapula. Both metastases were surgically resected, and no additional treatment was administered. At the time of this writing, there had been no recurrence or metastasis for 42 months following the second metastasectomy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Metastasectomy may be an effective treatment option for solitary metastasis of LCNEC of the bladder.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 6","pages":"612-616"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70102","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A certain proportion of prostate cancers have alterations in homologous recombination repair (HRR)- related genes. poly ADP-ribose polymerase (PARP) inhibitors have been approved for metastatic castration-resistant prostate cancer (mCRPC) with mutations in the BRCA1/2 gene. For other HRR-related genes, there is insufficient evidence to determine whether PARP inhibitors are effective or not.
Case Presentation
The patient was a 59-year-old man with mCRPC. FoundationOne CDx was performed using surgical specimens and detected a pathogenic variant of the RAD54L gene, and the expert panel recommended administration of niraparib by patient-proposed healthcare services. Therefore, the patient was enrolled in the BELIEVE Trial and started on niraparib, which showed a marked decrease in PSA and a reduction in metastatic lesions. However, PSA subsequently began to rise and metastatic lesions were enlarged, so treatment was discontinued at 25 weeks.
Conclusion
Niraparib was effective for mCRPC with RAD54L gene mutation.
Trial Registration
The prospective trial of patient-proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE) (NCCH1901/jRCTs031190104)
{"title":"A Case of Metastatic Castration-Resistant Prostate Cancer With RAD54L Mutation Responding to Niraparib","authors":"Yusuke Sato, Yoichi Fujii, Masaki Nakamura, Chiharu Tanai, Yuta Yamada, Kousuke Watanabe, Hidenori Kage, Kuniko Sunami, Katsutoshi Oda, Haruki Kume","doi":"10.1002/iju5.70093","DOIUrl":"https://doi.org/10.1002/iju5.70093","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>A certain proportion of prostate cancers have alterations in homologous recombination repair (HRR)- related genes. poly ADP-ribose polymerase (PARP) inhibitors have been approved for metastatic castration-resistant prostate cancer (mCRPC) with mutations in the <i>BRCA1/2</i> gene. For other HRR-related genes, there is insufficient evidence to determine whether PARP inhibitors are effective or not.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>The patient was a 59-year-old man with mCRPC. FoundationOne CDx was performed using surgical specimens and detected a pathogenic variant of the <i>RAD54L</i> gene, and the expert panel recommended administration of niraparib by patient-proposed healthcare services. Therefore, the patient was enrolled in the BELIEVE Trial and started on niraparib, which showed a marked decrease in PSA and a reduction in metastatic lesions. However, PSA subsequently began to rise and metastatic lesions were enlarged, so treatment was discontinued at 25 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Niraparib was effective for mCRPC with <i>RAD54L</i> gene mutation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>The prospective trial of patient-proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE) (NCCH1901/jRCTs031190104)</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 6","pages":"578-582"},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70093","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laparoscopic heminephrectomy for renal cell carcinoma in horseshoe kidneys has been previously reported, but reports on the retroperitoneal approach remain limited. This paper presents a case demonstrating the feasibility and effectiveness of this surgical technique.
Case Presentation
A 74-year-old woman was diagnosed with two renal cell carcinomas in the right side of a horseshoe kidney in contrast-enhanced computed tomography. A laparoscopic right heminephrectomy was performed using a retroperitoneal approach. This approach allowed for effective management of the complex vasculature supplying the isthmus. Additionally, the inferior mesenteric artery served as a reliable anatomical landmark, facilitating the identification of the optimal site for isthmus transection.
Conclusion
Retroperitoneoscopic heminephrectomy is a safe and effective surgical option for renal cell carcinoma in patients with horseshoe kidneys and represents an anatomically rational approach.
{"title":"Retroperitoneal Laparoscopic Right Heminephrectomy for Renal Cell Carcinoma in a Horseshoe Kidney","authors":"Yusuke Andoh, Atsuhiko Ochi, Hidetsugu Takahashi, Minoru Nakazono, Akira Komiya, Hiroshi Kuji, Koichiro Suzuki, Naoki Shiga, Takahiro Kimura, Hirokazu Abe","doi":"10.1002/iju5.70098","DOIUrl":"https://doi.org/10.1002/iju5.70098","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Laparoscopic heminephrectomy for renal cell carcinoma in horseshoe kidneys has been previously reported, but reports on the retroperitoneal approach remain limited. This paper presents a case demonstrating the feasibility and effectiveness of this surgical technique.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>A 74-year-old woman was diagnosed with two renal cell carcinomas in the right side of a horseshoe kidney in contrast-enhanced computed tomography. A laparoscopic right heminephrectomy was performed using a retroperitoneal approach. This approach allowed for effective management of the complex vasculature supplying the isthmus. Additionally, the inferior mesenteric artery served as a reliable anatomical landmark, facilitating the identification of the optimal site for isthmus transection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Retroperitoneoscopic heminephrectomy is a safe and effective surgical option for renal cell carcinoma in patients with horseshoe kidneys and represents an anatomically rational approach.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 6","pages":"596-600"},"PeriodicalIF":0.0,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70098","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lenvatinib (LEN) concentrations in patients undergoing hemodialysis (HD) have not been examined. Herein, we report the effect of HD on total and free LEN concentrations in a patient with mRCC.
Case Presentation
The hemodialyzed patient was a 55-year-old Japanese male who was treated with 20 mg LEN daily. The area under the plasma concentration–time curve for LEN from 0 to 24 h (AUC0–24) was calculated on Day 8 (off HD) and Day 9 (on HD) after starting administration of LEN. For total LEN on Days 8 and 9, the AUC0–24 was 2553 and 2783 ng × h/mL, respectively. The free LEN concentration just after HD on Day 9 was 40% lower than that at the same time on Day 8 (1.8 vs. 3.0 ng/mL).
Conclusion
Although the free LEN concentration is reduced just after HD, LEN will have sufficient pharmacological activity on HD days for patients undergoing HD.
尚未对血液透析（HD）患者的Lenvatinib （LEN）浓度进行检测。在此，我们报告了HD对mRCC患者总和游离LEN浓度的影响。血液透析患者是一名55岁的日本男性，每日服用20mg LEN。在开始给药LEN后第8天（无HD）和第9天（无HD）计算LEN 0 - 24 h血浆浓度-时间曲线下面积（AUC0-24）。第8天和第9天的总LEN， AUC0-24分别为2553和2783 ng × h/mL。HD后第9天的游离LEN浓度比第8天的同一时间低40% （1.8 vs. 3.0 ng/mL）。结论虽然HD刚发生时游离LEN浓度降低，但对于HD患者，LEN在HD日仍具有足够的药理活性。
{"title":"Effect of Hemodialysis on Total and Free Lenvatinib Concentrations in a Patient With Metastatic Renal Cell Carcinoma","authors":"Takahiro Ito, Shimpei Yamashita, Manabu Suno, Ayaka Iwata, Yasuo Kohjimoto, Kazuo Matsubara","doi":"10.1002/iju5.70099","DOIUrl":"https://doi.org/10.1002/iju5.70099","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Lenvatinib (LEN) concentrations in patients undergoing hemodialysis (HD) have not been examined. Herein, we report the effect of HD on total and free LEN concentrations in a patient with mRCC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>The hemodialyzed patient was a 55-year-old Japanese male who was treated with 20 mg LEN daily. The area under the plasma concentration–time curve for LEN from 0 to 24 h (AUC<sub>0–24</sub>) was calculated on Day 8 (off HD) and Day 9 (on HD) after starting administration of LEN. For total LEN on Days 8 and 9, the AUC<sub>0–24</sub> was 2553 and 2783 ng × h/mL, respectively. The free LEN concentration just after HD on Day 9 was 40% lower than that at the same time on Day 8 (1.8 vs. 3.0 ng/mL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although the free LEN concentration is reduced just after HD, LEN will have sufficient pharmacological activity on HD days for patients undergoing HD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 6","pages":"601-603"},"PeriodicalIF":0.0,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70099","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号